Briefing documents released ahead of the Endocrinologic and Metabolic Drugs Advisory Committee meeting Tuesday for Mannkind Corp.’s regulatory-plagued inhaled insulin candidate, Afrezza, indicate that executives of the Valencia, Calif.-based firm have their work cut out for them.